QIAGEN Partners With FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law en
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution for Oncology and Inherited Disease Applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances p
Qiagen Is Maintained at Hold by Stifel
Qiagen Is Maintained at Hold by Stifel
Stifel Maintains Hold on Qiagen, Lowers Price Target to $45
Stifel analyst Daniel Arias maintains Qiagen with a Hold and lowers the price target from $55 to $45.
Qiagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 6.31% Stifel $55 → $45 Maintains Hold 02/16/2024 20.48% Morgan Stanley $49.48 → $51 Upgrades Eq
Earnings Call Summary | Qiagen NV(QGEN.US) Q1 2024 Earnings Conference
The following is a summary of the Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript:Financial Performance:Qiagen reported Q1 2024 net sales of $462 million at constant exchange rates, an improvement
Deutsche Bank Remains a Buy on Qiagen (QGEN)
UBS Sticks to Its Hold Rating for Qiagen (QGEN)
Qiagen Shares Tumble on Lowered Guidance Despite Q1 Beat
Qiagen N.V. (NYSE: NYSE:QGEN) reported first-quarter earnings that edged past analysts' expectations but provided a full-year outlook that fell short of consensus estimates, prompting a 7.84% slide in its shares.
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours
Qiagen (QGEN) reported Q1 adjusted earnings Monday of $0.46 per diluted share, down from $0.51 per share a year earlier. Analysts polled by Capital IQ expected $0.44. Net sales for the quarter ended M
QIAGEN Reaffirms FY24 Adj. EPS $2.10 Vs $2.11 Est.; Net Sales $2.0B Vs $2.010B Est.
QIAGEN Reaffirms FY24 Adj. EPS $2.10 Vs $2.11 Est.; Net Sales $2.0B Vs $2.010B Est.
Qiagen Q1 2024 Adj EPS $0.46 Beats $0.44 Estimate, Sales $458.796M Beat $457.330M Estimate
Qiagen (NYSE:QGEN) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.44 by 4.55 percent. This is a 9.8 percent decrease over earnings of $0.51 per share fr
QIAGEN Reports Results for Q1 2024 Ahead of Outlook, on Track to Achieve Full-year 2024 Guidance
Venlo, the Netherlands, April 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the first quarter of 2024. Net sales declined 5% to $459 million, while
Qiagen Q1 2024 Earnings Preview
Investors Interested In Qiagen N.V.'s (NYSE:QGEN) Earnings
Qiagen N.V.'s (NYSE:QGEN) price-to-earnings (or "P/E") ratio of 26.9x might make it look like a strong sell right now compared to the market in the United States, where around half of the companies ha
QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB)
Bank of America Securities Reaffirms Their Buy Rating on Qiagen (QGEN)
QIAGEN N.V. to Release Results for Q1 2024 and Hold Webcast
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date
Qiagen N.V.'s (NYSE:QGEN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Qiagen (NYSE:QGEN) has had a rough three months with its share price down 12%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean th
No Data